Pharmacy & Pharmacology最新文献

筛选
英文 中文
Use of gabapentin for neuropathic pain therapy: A view from perspective of evidence-based medicine 使用加巴喷丁治疗神经病理性疼痛:从循证医学的角度看问题
Pharmacy & Pharmacology Pub Date : 2024-05-09 DOI: 10.19163/2307-9266-2024-12-1-74-88
O. Butranova, S. Zyryanov
{"title":"Use of gabapentin for neuropathic pain therapy: A view from perspective of evidence-based medicine","authors":"O. Butranova, S. Zyryanov","doi":"10.19163/2307-9266-2024-12-1-74-88","DOIUrl":"https://doi.org/10.19163/2307-9266-2024-12-1-74-88","url":null,"abstract":"The aim of the study was to analyze the literature sources for pharmacodynamic and pharmacokinetic features of gabapentin, providing its use in patients with neuropathic pain, as well as a comparative evaluation of its efficacy and safety when used in different doses.Materials and methods. PubMed, Google Scholar, EMBASE, ResearchGate scientific information network and elibrary.ru databases were used as search resources. The keywords used for the search were “gabapentin”, “mechanism of action”, “gabapentin targets”, “gabapentin pharmacodynamics”, “pharmacokinetics”, “pharmacokinetic parameters”, “neuropathic pain”, and “randomized clinical trials”. The depth of the search was 26 years (from 1998 to 2024). This review resulted in 87 literature sources.Results. Neuropathic pain (NeP) is one of the most common types of chronic pain, characterized by a high prevalence among people of the working age. Effective pharmacotherapy aimed at eliminating the pain syndrome is a key tool for improving the quality of life and preserving the work capacity of patients. Heterogeneity of etiologic factors involved in the genesis of NeP indicates the need to use drugs the analgesic effect of which is based on weakening the transmission of pain impulses in the CNS. In clinical trials, gabapentin has demonstrated efficacy in reducing the severity of pain in patients with postherpetic NeP, painful diabetic neuropathy and many other conditions accompanied by NeP. The dose of gabapentin 300 mg/day is the initial dose in the therapy of NeP and requires a further slow titration depending on the patient’s response to therapy and tolerability of the drug, especially in elderly and senile patients, as well as in patients with an impaired renal function. According to the published data, the most pronounced analgesic effect is achieved in the patients against the background of the gabapentin administration at a dose of 3600 mg/day.Conclusion. Gabapentin is the drug of choice in the management of patients with NeP of different etiology and intensity. A satisfactory safety profile and pharmacodynamic effects make gabapentin possible, despite the long history of its use, to remain a relevant drug used by a wide range of physicians, specialties, for pharmacotherapy of NeP patients.","PeriodicalId":513390,"journal":{"name":"Pharmacy & Pharmacology","volume":" 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140997186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigator’s influence on the muscle strength assessment in animals in experiment: Comparison of automated “inverted grid” test and its classical variant 研究人员对实验中动物肌肉力量评估的影响:自动 "倒网格 "测试与其经典变体的比较
Pharmacy & Pharmacology Pub Date : 2024-05-08 DOI: 10.19163/2307-9266-2024-12-1-63-73
P. Lebedev, E. Kuzubova, V. M. Pokrovsky, A. Radchenko, S. I. Osipyan, Yulia V. Stepenko, A. A. Apostol, L. M. Danilenko, A. Dolzhikov, T. G. Pokrovskaya, O. Gudyrev, Ya. S. Kochergina, O. V. Dudnikova
{"title":"Investigator’s influence on the muscle strength assessment in animals in experiment: Comparison of automated “inverted grid” test and its classical variant","authors":"P. Lebedev, E. Kuzubova, V. M. Pokrovsky, A. Radchenko, S. I. Osipyan, Yulia V. Stepenko, A. A. Apostol, L. M. Danilenko, A. Dolzhikov, T. G. Pokrovskaya, O. Gudyrev, Ya. S. Kochergina, O. V. Dudnikova","doi":"10.19163/2307-9266-2024-12-1-63-73","DOIUrl":"https://doi.org/10.19163/2307-9266-2024-12-1-63-73","url":null,"abstract":"The aim of the work was to study the influence of the researcher on the muscle strength assessment in animals in the experiment by comparing the results of the automated “inverted grid” test and its classical variant.Materials and methods. Male lines (Bla/J, n=20; FUS(1-359), n=20; Tau P301S+/+, n=20) and their background controls (C57BL/6J, n=20; CD1, n=20) were selected for the study. The dynamics of changes in the muscle deficit of the animals was evaluated in the automated and classical variant of the “inverted grid” test.Results. According to the results of the muscle strength assessment of mice with an edited genome of lines FUS(1-359)+/-, Tau P301S+/+, B6.ADysfprmd/GeneJ, using the “inverted grid” test in the classical variant and the automated one, it was found that statistically significant differences were not obtained in comparison with the results obtained by the classical variant of the test. The standard error of the mean increases by 23–39% in the classical test compared to the automated one. It was shown that the standard error of the mean in the classical variant of the test in Tau P301S+/+ mice was 6.24; 5.94; 5.88; 7.38 at 4 age points; in FUS(1-359)+/- mice, 4.49; 6.8; 6.98 and 4.1; B6.ADysfprmd/GeneJ mice, 7.66; 7.58; 8.3 and 7.92, respectively.Conclusion. Thus, the value of the standard error of the results study mean of the changes dynamics in the muscle strength when using the automated variant of the “inverted grid” test was reduced in comparison with the results of the classical variant of the test. The results of the study show that the automation of generally recognized behavioral tests is able to increase the accuracy of the obtained data reducing the influence of a human factor on the manipulation.","PeriodicalId":513390,"journal":{"name":"Pharmacy & Pharmacology","volume":" 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140998621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of CYP3A4*1B, CYP3A4*22 and CYP3A5*3 polymorphisms carriage with efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia CYP3A4*1B、CYP3A4*22 和 CYP3A5*3 多态性载体与良性前列腺增生患者服用坦索罗辛的疗效和安全性的关系
Pharmacy & Pharmacology Pub Date : 2024-05-08 DOI: 10.19163/2307-9266-2024-12-1-32-48
S. Abdullaev, M. Shatokhin, O. L. Sigailo, S. Abdullaev, P. O. Bochkov, S. N. Tuchkova, O. V. Teodorovich, O. B. Loran, D. Sychev
{"title":"Association of CYP3A4*1B, CYP3A4*22 and CYP3A5*3 polymorphisms carriage with efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia","authors":"S. Abdullaev, M. Shatokhin, O. L. Sigailo, S. Abdullaev, P. O. Bochkov, S. N. Tuchkova, O. V. Teodorovich, O. B. Loran, D. Sychev","doi":"10.19163/2307-9266-2024-12-1-32-48","DOIUrl":"https://doi.org/10.19163/2307-9266-2024-12-1-32-48","url":null,"abstract":"Tamsulosin is a first-line drug in the treatment of lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH). Despite high estimates of its efficacy and safety, it rates may vary due to genetic polymorphisms of genes for the enzymes involved in the drugs metabolism.The aim of the work was to evaluate the carriage influence of genes polymorphisms of the CYP3A enzymes group of tamsulosin metabolizers on the efficacy and safety of therapy in patients with LUTS in BPH.Materials and methods. A total of 142 patients with LUTS, with an established BPH diagnosis (N40 according to ICD-10) were included in the study and underwent all stages. All patients received monotherapy with tamsulosin 0.4 mg/day for at least 8 weeks. An IPSS questionnaire with the definition of quality of life, a prostate ultrasound with the determination of the prostate volume and residual urine, as well as uroflowmetry, were used to evaluate the results of the treatment. Controls were performed at 2, 4 and 8 weeks from the start of the therapy. The carriage of polymorphic markers CYP3A4 (*1B, *22) and CYP3A5*3 was determined in patients; HPLC was used to determine drug concentrations in blood plasma and levels of cortisol and its metabolite 6-beta-hydroxycortisol in urine to assess the phenotypic activity of CYP3A.Results. No statistically significant associations between CYP3A phenotype (defined by CYP3A4 and CYP3A5 genotypes) and clinical parameters of the tamsulosin therapy efficacy and the safety assessment in the studied sample of patients were found (p >0.05). Similar data were obtained for individual variants of CYP3A4*1B, CYP3A4*22, CYP3A5*3 (p >0.05). The comparison of the tamsulosin residual equilibrium concentration values in patients in the study sample with respect to the carriers of CYP3A4 and CYP3A5 gene variants did not reveal the presence of significant differences in either CYP3A phenotypes  and carriers and non-carriers of individual CYP3A4*1B (p=0.57), CYP3A4*22 (p=0.37) and CYP3A5*3 (p=0.76) variants. No association was found between the metabolic ratio of 6-beta-hydroxycortisol / cortisol in urine and the CYP3A phenotype encoded by a combination of genotypes of CYP3A4 and CYP3A5 gene variants (p >0.05).Conclusion. A possible association between the carriage of CYP3A4*1B, CYP3A4*22, CYP3A5*3 variants, a CYP3A activity assessed by the content of an endogenous substrate of this isoenzyme and its metabolite in urine, the level of plasma concentration of the drug, and the efficacy and safety of tamsulosin, has not been confirmed. The contribution of CYP3A4 and CYP3A5 genetic polymorphisms to clinical parameters of the tamsulosin therapy requires a further study.","PeriodicalId":513390,"journal":{"name":"Pharmacy & Pharmacology","volume":" 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140998436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a method for quantitative determination of nitric oxide (NO) in rat tissues based on high-performance liquid chromatography and mass spectrometry 基于高效液相色谱和质谱法建立大鼠组织中一氧化氮(NO)的定量测定方法
Pharmacy & Pharmacology Pub Date : 2024-05-08 DOI: 10.19163/2307-9266-2024-12-1-49-62
N. Popov, D. A. Gavrilenko, M. S. Baranov, V. Yu. Balabanyan
{"title":"Development of a method for quantitative determination of nitric oxide (NO) in rat tissues based on high-performance liquid chromatography and mass spectrometry","authors":"N. Popov, D. A. Gavrilenko, M. S. Baranov, V. Yu. Balabanyan","doi":"10.19163/2307-9266-2024-12-1-49-62","DOIUrl":"https://doi.org/10.19163/2307-9266-2024-12-1-49-62","url":null,"abstract":"A quantitative assessment of nitric oxide (NO) production in body tissues is an urgent problem in pharmacology and biochemistry. The study of physiological processes occurring with the participation of NO, as well as the metabolism and pharmacodynamics of pharmacological agents from the group of NO donors, requires the introduction of accurate and reproducible methods for the quantitative determination of this metabolite in biological media.The aim of the study was to develop the HPLC-MS/MS methods for the quantitative determination of NO in various tissues of rats.Materials and methods. The indirect NO quantification was based on estimation of the level of more stable metabolites: nitrites and nitrates extracted from rat tissues by homogenization with water. The reduction of nitrates to nitrites was carried out using nitrate reductase. The derivatization of nitrites was based on a reaction with Griess reagent. The resulting azo dye was determined by HPLC-MS/MS using an Agilent InfinityLab Poroshell 120 EC-C18 4.6×100 mm, 2.7 μm analytical column. The total chromatographic analysis time was 12 minutes, and the analyte retention time was 6.1 minutes. The analytical range of the method was 0.1–100.0 nmol (in terms of nitrite) per 1 ml of plasma or tissue homogenate.Results. The developed a bioanalytical method was validated according to the following parameters: a selectivity, a matrix effect, a recovery degree, a sample transfer, an analytical range linearity, a lower limit of quantification (LLOQ), an intra- and inter-assay accuracy and precision, and a stability at all the stages of the analysis. To test the method, the NO content in the plasma, brain, heart, aorta and lungs of rats was determined.Conclusion. The developed bioanalytical HPLC-MS/MS methods fully meets the validation requirements. The metrological characteristics of the technique make it possible to highly accurately estimate the NO production in various tissues of rats, which is undoubtedly relevant and in demand in the study of pathological processes as well as the mechanism of action of pharmacological agents from the group of NO donors.","PeriodicalId":513390,"journal":{"name":"Pharmacy & Pharmacology","volume":" 13","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140998999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness assessment of sulfur-containing amino acids in rats with experimental “alcohol withdrawal syndrome” with modified zoosocial interaction methods 用改良的动物社会互动方法评估含硫氨基酸对实验性 "酒精戒断综合征 "大鼠的疗效
Pharmacy & Pharmacology Pub Date : 2024-05-07 DOI: 10.19163/2307-9266-2024-12-1-4-14
V. I. Petrov, N. A. Osadchenko, A. Tarasov, A. M. Dotsenko, E. I. Morkovin
{"title":"Effectiveness assessment of sulfur-containing amino acids in rats with experimental “alcohol withdrawal syndrome” with modified zoosocial interaction methods","authors":"V. I. Petrov, N. A. Osadchenko, A. Tarasov, A. M. Dotsenko, E. I. Morkovin","doi":"10.19163/2307-9266-2024-12-1-4-14","DOIUrl":"https://doi.org/10.19163/2307-9266-2024-12-1-4-14","url":null,"abstract":"The aim of the work was to compare the effects of ademethionine, acetylcysteine and taurine on the zoosocial behavior of rats in a post-intoxicated state after an acute ethanol poisoning.Materials and methods. The study was conducted on male rats of the Wistar line. The post-intoxication state was modeled by a single injection of ethanol (3 g/kg, intraperitoneally). 30 min after awakening, the animals were injected with a physiological solution, acetylcysteine (1 g/kg), ademetionine (100 mg/kg) or taurine (40 mg/kg). A zoosocial interaction test was performed 30 min after the administration.Results. Among the behavioral indicators investigated, the following were validated: the number of acts of freezing, their duration, the number of acts of sniffing in front, the number of acts of avoidance and the number of vertical stances without support (p <0.05 between the values of the negative and positive control groups in all cases). The administration of acetylcysteine, ademetionine and taurine reduced the number of freezing acts by 53.64, 7.27 and 24.51%, respectively (p <0.05 when compared with the indicator index in the animals from the positive control group in all cases). The administration of acetylcysteine and taurine reduced the number of avoidance acts by 50 and 10%, respectively (p <0.05 when compared to that of the animals from the positive control group in both cases). All amino acids normalized the communicative performance, although it did not differ from that of the animals from the positive control group (p >0.05). Alcoholization reduced the number of vertical stances by 65% (p <0.001 when compared with that in the animals from the negative control group), and when followed by the administration of ademetionine and taurine, the reduction was 38 and 36%, respectively (p <0.05 when compared to that in the animals from the negative control group).Conclusion. According to the data obtained, sulfur-containing amino acids, primarily those that had central effects, normalized neuronal functions, positively influencing a complex behavior of rats. Taking into account the results of the previous studies, it was possible to conclude that the therapeutic effect of ademetionine and taurine in the context of a post-intoxication state is mediated by their central effects, which are not so pronounced in comparison with acetylcysteine.","PeriodicalId":513390,"journal":{"name":"Pharmacy &amp; Pharmacology","volume":"61 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141002385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of actual results of drug supply implementation within framework of High-Cost Nosologies Program 在高成本鼻疽方案框架内实施药物供应的实际结果分析
Pharmacy &amp; Pharmacology Pub Date : 2024-05-07 DOI: 10.19163/2307-9266-2024-12-1-15-31
O. Ivakhnenko, V. V. Ryazhenov, E. A. Maksimkina, V. S. Fisenko, O. V. Savoskin, M. M. Kuznetsova
{"title":"Analysis of actual results of drug supply implementation within framework of High-Cost Nosologies Program","authors":"O. Ivakhnenko, V. V. Ryazhenov, E. A. Maksimkina, V. S. Fisenko, O. V. Savoskin, M. M. Kuznetsova","doi":"10.19163/2307-9266-2024-12-1-15-31","DOIUrl":"https://doi.org/10.19163/2307-9266-2024-12-1-15-31","url":null,"abstract":"The accessibility and pharmaceutical care coverage are linked to political, economic and managerial decisions. That fact necessitates the evaluation of the state programs results in the field of the drug provision.The aim of the work was to assess the quantitative results of the implementation of the High-Cost Nosologies program in the Russian Federation from 2008 to 2023 to determine further vectors of its improvement.Materials and methods. The regulatory base of the work was made up of the Russian Federation legislation in the field of the drug provision. The open sources were used as the research information base for the data collection and analysis: reports of federal and regional executive authorities, materials of specialized conferences, results of published studies.Results. The drug coverage under the High-Cost Nosologies (VZN) program is provided for 14 nosologies, 11 of which are classified as orphan diseases. Since its implementation, the HCNs program has been expanded twice by including new nosologies in 2019 and 2020. As of 01 October 2023, the number of patients in the Federal Register of VZN was 263 721 people, which was 13.58 times greater compared to 2008. The drug provision is carried out according to the list of 47 INNs. The amount of funding for the program increased from RUB 32 bn in 2008 to RUB 87.96 bn in 2023. The most resource-intensive nosologies include hemophilia, multiple sclerosis and oncohematology.Conclusion. The main quantitative characteristics of the implementation of the HCNs program and the identified vectors for its further improvement have been analyzed in this study. The results obtained can be used to conduct analytical studies, including the ones within nosologies and nosological groups included in the program, in order to optimize a pharmaceutical care. The focus of improving the implementation of the VZN program is related to the improvement of the legal framework, a patient treatment paradigm and approaches to its financing.","PeriodicalId":513390,"journal":{"name":"Pharmacy &amp; Pharmacology","volume":"22 23","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141005955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Composition and technology development of ear drops with cerumenolytic action (based on thick Viscum album L. leaves extract) 具有耵聍分解作用的滴耳液(基于厚朴叶提取物)的成分和技术开发
Pharmacy &amp; Pharmacology Pub Date : 2024-01-30 DOI: 10.19163/2307-9266-2023-11-6-482-493
A. E. Pozdnyakova, S. Adzhiakhmetova, E. O. Sergeeva, D. I. Pozdnyakov, E. A. Yurtaeva, I. O. Borodina, D. Kompantsev
{"title":"Composition and technology development of ear drops with cerumenolytic action (based on thick Viscum album L. leaves extract)","authors":"A. E. Pozdnyakova, S. Adzhiakhmetova, E. O. Sergeeva, D. I. Pozdnyakov, E. A. Yurtaeva, I. O. Borodina, D. Kompantsev","doi":"10.19163/2307-9266-2023-11-6-482-493","DOIUrl":"https://doi.org/10.19163/2307-9266-2023-11-6-482-493","url":null,"abstract":"Earwaxes lead to a decrease in the quality of life. A rational and effective way to eliminate earwaxes without a participation of medical personnel is to use ear drops and solutions to dissolve sulfur masses. In this regard, therapeutic and hygienic drops of а cerumenolytic action are of a particular relevance in the pharmaceutical market.The aim of the work was to develop a composition and technology of ear drops of a cerumenolytic action based on thick Viscum Album L. leaves extract.Materials and methods. The objects of the study were thick Viscum Album L. leaf extract, chitosan, sodium alginate, polyethylene oxide of various degrees of polymerization, propylene glycol, sodium hyaluronate, preservatives (benzalkonium chloride, nipagine and nipazole). At the screening stage, 9 experimental formulations were proposed. The cerumenolytic activity of the developed formulations was evaluated in a dissolution test of reproduced artificial earwax in comparison with a 3% hydrogen peroxide solution, TEA-cocoyl hydrolyzed collagen (A-Cerumen Plus, Gilbert Laboratories, France) and a 0.9% sodium chloride solution. Physical and chemical parameters (a degree of liquid coloring, turbidity and transparency, pH, density and viscosity) were determined according to of the State Pharmacopoeia of the Russian Federation (XV ed.). The microbiological study was performed using the agar diffusion method.Results. In the course of the study, it was shown that the composition of ear drops of a cerumenolytic action based on thick Viscum Album L. leaves extract, exceeds the level of a lipolytic, proteolytic and general cerumenolytic kinds of activity of the compositions containing surfactants; in its effectiveness, it was comparable with the comparison drug – A-Cerumen drops. To obtain the optimal rate of the onset effect and its duration, it is advisable to use sodium hyaluronate in the amount of 0.2 g per 25 ml of drops as an adjuvant. The most preferred preservative was benzalkonium chloride. The developed ear drops met the requirements of the State Pharmacopoeia of the Russian Federation (XV ed.) for this dosage form, while the pH was 5.86± 0.1, and the viscosity was 4.2676±0.2 MPa×s.Conclusion. The conducted research has shown the prospects for further work on the development and implementation of ear drops of a cerumenolytic action in practice. The recommended composition is the following: thick Viscum Album L. leaf extract, sodium hyaluronate, benzalkonium chloride, purified water.","PeriodicalId":513390,"journal":{"name":"Pharmacy &amp; Pharmacology","volume":"389 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140480153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Terpenoids and phenolic compounds as biologically active compounds of medicinal plants with diuretic effect 萜类和酚类化合物是具有利尿作用的药用植物的生物活性化合物
Pharmacy &amp; Pharmacology Pub Date : 2024-01-30 DOI: 10.19163/2307-9266-2023-11-6-446-460
V. A. Kurkin, O. Pravdivtseva, E. N. Zaitseva, A. V. Dubishchev, A. S. Tsibina, A. Kurkina, S. V. Pervushkin, A. Zhdanova
{"title":"Terpenoids and phenolic compounds as biologically active compounds of medicinal plants with diuretic effect","authors":"V. A. Kurkin, O. Pravdivtseva, E. N. Zaitseva, A. V. Dubishchev, A. S. Tsibina, A. Kurkina, S. V. Pervushkin, A. Zhdanova","doi":"10.19163/2307-9266-2023-11-6-446-460","DOIUrl":"https://doi.org/10.19163/2307-9266-2023-11-6-446-460","url":null,"abstract":"The aim of the study was to summarize and systematize the literature data, as well as the results of the carried out research in the field of medicinal plants used as diuretics in the Russian Federation and abroad.Materials and methods. During the search for this review article materials, the abstract databases of PubMed, Google Scholar, as well as the ResearchGate and elibrary.ru were used. The search was carried out according to the publications for the period from 2005 to 2023. The keywords were as follows: herbal diuretics, diuretic drugs, kidney diseases, types of medicinal plant raw materials. The data from the authors’ previous scientific research on the analysis of the diuretic properties of certain types of medicinal plant raw materials, as well as individual substances of a phenolic nature isolated from them (simple phenols, flavonoids), were also reviewed.Results. It was determined that the diuretic activity of most of the medicinal plants used, is due to such groups of biologically active compounds as terpenoids (essential oils and saponins), simple phenols, flavonoids and anthracene derivatives related to the secondary metabolites. It has been shown that, despite the fact that many herbal diuretics have concomitant anti-inflammatory, antimicrobial, antiviral, antihistamine and other properties relevant from the point of view of etiology and pathogenesis of the disease, it is reasonable to use them as part of collections of medicinal plants and other combined medicinal herbal preparations, as this is in accordance with the global trend. The types of medicinal plant raw materials that can be a promising source of new diuretic herbal medicines, have been examined in this review.Conclusion. It has been determined that terpenoids and phenolic compounds make the greatest contribution to the manifestation of the diuretic activity of medicinal herbal preparations, among which the greatest structural diversity is noted for flavonoids. It has been established that in the composition of any drug, taking into account the peculiarities of etiology and pathogenesis of the disease, herbal diuretics can be both the main drug and an auxiliary component. The expediency of using medicinal plant raw materials with a diuretic effect as part of collections of medicinal plants and other combined preparations used in the treatment of kidney and urinary tract diseases has been also substantiated.","PeriodicalId":513390,"journal":{"name":"Pharmacy &amp; Pharmacology","volume":"63 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140481712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hospital consumption of direct oral anticoagulants in regions of the Russian Federation in 2017–2022 2017-2022 年俄罗斯联邦各地区医院直接口服抗凝剂的消耗量
Pharmacy &amp; Pharmacology Pub Date : 2024-01-30 DOI: 10.19163/2307-9266-2023-11-6-461-470
A. Matveev, S. V. Glagolev, K. N. Koryanova, D. Sychev
{"title":"Hospital consumption of direct oral anticoagulants in regions of the Russian Federation in 2017–2022","authors":"A. Matveev, S. V. Glagolev, K. N. Koryanova, D. Sychev","doi":"10.19163/2307-9266-2023-11-6-461-470","DOIUrl":"https://doi.org/10.19163/2307-9266-2023-11-6-461-470","url":null,"abstract":"The aim of the study was to investigate the dynamics of inpatient consumption of direct oral anticoagulants in different regions of the Russian Federation for the period from 2017 to 2022.Materials and methods. This study is a non-interventional, retrospective analysis of the electronic database records of Cursor Marketing LLC (Russia) about the announced by medical organizations and executed contracts for the purchase of direct oral anticoagulants (DOACs). The сonsumption was calculated on the basis of a DDD (defined-daily-dose) and estimated DDDTID (defined-daily-dose/1000-inhabitants/day) for each DOACs: rivaroxaban, dabigatran and apixaban. The Rosstat database available on its official website were used as a source of inhabitants data for the Russian regions.Results. A total of 57 866 records were entered into the analyzed databases of Cursor Marketing LLC (Russia) from 2017 to 2022, 47.38% of which indicated rivaroxaban as the drug being procured, 26.51% indicated dabigatran, and 26.11% indicated apixaban. Edoxaban was not procured by healthcare organizations. During the period investigated, there was an increase in the consumption of all DOACs studied, with a higher increase for apixaban (by an average of 284.6% per year), then rivaroxaban (by 144.8% per year) and, to a lesser extent, dabigatran (by 92.5% per year). The analysis of DOACs consumption in general showed that compared to 2017, the need for these drugs in medical organizations in 2022 increased by 18 times. The Urals Federal District consistently exceeds the national average in terms of DDTID consumption. Noteworthy is the consumption dynamics of the regions of the Central Federal District and the North-Western Federal District, which made it possible to achieve DDDTID values above the national average for 5 out of 6 observation years. The lowest rates of DOACs consumption were observed in the Volga Federal District, which, despite positive growth dynamics, failed to reach the national average values. A high level of consumption (>10 DDDTID) of rivaroxaban was noted for the Arkhangelsk region (2018) and the Nenets Autonomous District (in 2021), dabigatran – only for the Arkhangelsk region (in 2018). Many more regions reached high levels of the apixaban consumption, especially in 2021.Conclusion. Despite a number of limitations, the data on the volume of DOACs procurement can be used in the analysis of the consumption at both regional and national levels. When analyzing the DOACs consumption, the impact of COVID-19 pandemic and pharmacogenetic features of patients in different regions should be taken into account. During the studied period of time, a significant part of the Russian regions achieved a consumption level of rivaroxaban and apixaban, but not dabigatran, exceeding 1 DDDTID.","PeriodicalId":513390,"journal":{"name":"Pharmacy &amp; Pharmacology","volume":"136 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140480600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of insertion/deletion polymorphism of angiotensin-converting enzyme gene on efficacy of antihypertensive therapy with angiotensin II receptor blockers 血管紧张素转换酶基因的插入/缺失多态性对血管紧张素 II 受体阻滞剂降压疗效的影响
Pharmacy &amp; Pharmacology Pub Date : 2024-01-30 DOI: 10.19163/2307-9266-2023-11-6-494-508
E. V. Rebrova, E. V. Shikh
{"title":"Effect of insertion/deletion polymorphism of angiotensin-converting enzyme gene on efficacy of antihypertensive therapy with angiotensin II receptor blockers","authors":"E. V. Rebrova, E. V. Shikh","doi":"10.19163/2307-9266-2023-11-6-494-508","DOIUrl":"https://doi.org/10.19163/2307-9266-2023-11-6-494-508","url":null,"abstract":"The efficacy of the antihypertensive therapy may be related to genetic factors that can influence not only the degree of the blood pressure (BP) elevation but also contribute to the interindividual variability of response to the antihypertensive treatment.The aim of the work was to study pharmacodynamic parameters of the therapy efficacy with angiotensin II receptor blockers in the form of monotherapy and as part of combined drugs in patients with the arterial hypertension depending on the genetic features of patients – polymorphism of the gene encoding angiotensin-converting enzyme, or I/D-polymorphism.Materials and methods. The study included 179 patients of the Moscow region with a first-diagnosed arterial hypertension (AH) of 1–2 degree, including 141 (78.8%) women and 38 (21.2%) men aged from 32 to 69 years. By a simple randomization method, the patients were randomly allocated into groups receiving irbesartan and valsartan as mono- or combination therapy with hydrochlorthiazide. After 3 weeks of this pharmacotherapy, the presence of rs4646994 Alu Ins / Del genetic polymorphism of the angiotensin-converting enzyme (ACE) gene and the minimum equilibrium concentration of angiotensin II receptor blockers (ARBs) were determined.Results. The patients treated with irbesartan, the D/D genotype carriers, were significantly less likely to reach the target BP and more likely to require a pharmacotherapy intensification compared to I/D heterozygotes (p=0.042 and p=0.058, respectively) and I/I homozygotes (p=0.011 and p=0.011, respectively). The patients treated with valsartan, the D/D genotype carriers, significantly more often reached the target BP and significantly less often required a pharmacotherapy intensification than the I/D genotype carriers (p=0.05 and p=0.05, respectively). Herewith, at the end of the study, according to the results of the office BP measurements and daily BP monitoring, the target BP achievement was not significantly correlated with the I/D polymorphism of the ACE gene.Conclusion. When personalizing the AH therapy in patients of the Moscow region, the genotype I/I carriers by I/D polymorphism of the ACE gene, can be recommended irbesartan in the form of mono- or bicomponent therapy as a starting therapy of ARBs; the D/D genotype carriers can be recommended valsartan. A more pronounced decrease in the daytime systolic BP (SBP), the daytime diastolic BP (DBP) and the nighttime SBP variabilities in the valsartan group of patients, the D allele carriers may indicate a more persistent effect of the antihypertensive therapy.","PeriodicalId":513390,"journal":{"name":"Pharmacy &amp; Pharmacology","volume":"84 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140482011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信